Hasegawa, Shinya
,
Sada, Ryuichi
Yaegashi, Makito
Morimoto, Konosuke
Mori, Takahiro http://orcid.org/0000-0003-0216-2284
Funding for this research was provided by:
Pfizer Japan
Article History
Received: 7 June 2019
Accepted: 3 October 2019
First Online: 26 December 2019
Ethics approval and consent to participate
: The APSG-J study adhered to the Guidelines for Ethical Aspects in Epidemiological Study (MHLW, 2008). Ethics approval was obtained by the Institutional Review Boards at all of the five study hospitals, namely the Institute of Tropical Medicine at Nagasaki University, Ebetsu City Hospital, Kameda Medical Center, Chikamori Hospital, and Juzenkai Hospital.This study was of noninterventional nature and did not include primary data collection (i.e., was based on published secondary data only). Therefore, ethic committee or institutional review board approval was not required. Data used were taken from published cohort trials, which were conducted according to the principles of the Declaration of Helsinki and with informed consent from participants. The APSG-J study was approved by the Institutional Review Boards in the Tropical Medicine at Nagasaki University, and the committee’s reference number was 11063070.
: Not applicable.
: KM reports and Grants from Pfizer, speaking fee from MSD and Pfizer. TM’s joint appointment as an associate professor at the University of Tsukuba was sponsored by JMDC Inc. in the 2018 financial year (i.e., April 2018 to March 2019), and by SMS CO., LTD. in the 2019 financial year (i.e., April 2019 to the present). JMDC Inc. or SMS CO., LTD had no role in conducting this study.